Approval · Notice of Compliance 26829 · 2021
SYNTHROID: Notice of Compliance 26829
Issued October 13, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 26829
- Date
- October 13, 2021
- Company
- BGP Pharma ULCEtobicoke, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Safety updates to the Product Monograph as per Advisement Letter and update to the 2020 format
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| SYNTHROID | Not yet assigned | — |
Medicinal ingredients
- LEVOTHYROXINE SODIUM 25 MCG per TAB
- LEVOTHYROXINE SODIUM 50 MCG per TAB
- LEVOTHYROXINE SODIUM 75 MCG per TAB
- LEVOTHYROXINE SODIUM 88 MCG per TAB
- LEVOTHYROXINE SODIUM 100 MCG per TAB
- LEVOTHYROXINE SODIUM 112 MCG per TAB
- LEVOTHYROXINE SODIUM 125 MCG per TAB
- LEVOTHYROXINE SODIUM 137 MCG per TAB
- LEVOTHYROXINE SODIUM 150 MCG per TAB
- LEVOTHYROXINE SODIUM 175 MCG per TAB
- LEVOTHYROXINE SODIUM 200 MCG per TAB
- LEVOTHYROXINE SODIUM 300 MCG per TAB